主页
市场
图表与思路
Algo
新闻
Store
经纪商
下载
经济日历
交易信号
网页端
键入
/
进行搜索:@user,$symbol
查找
登录
创建账户
中文
English
Русский
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
LPCN
#3478
Lipocine Inc.
9.960
0
+4.73%
版块:
基础:
利润货币:
日范围
年范围
日变化
+4.73%
每月变动
-0.10%
6个月变化
+243.45%
年变化
+243.45%
前一天收盘价
9.510
0
Open
9.960
0
Bid
Ask
Low
9.960
0
High
9.960
0
交易量
6
市场
股票
医疗保健
LPCN
Open full chart
Financials
Overview
声明
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
5.19 M
5.19 M
5.21 M
5.32 M
5.35 M
—
Valuation ratios
Enterprise value
—
—
—
10.43 M
19.9 M
56.57 M
Price to earnings ratio
—
—
—
-0.91
—
—
Price to sales ratio
—
—
—
-5.29
2.36
14.68
Price to cash flow ratio
—
—
—
-1.27
-21.67
-31.05
Price to book ratio
—
—
—
0.74
1.26
1.91
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.83
-0.01
-0.29
-0.71
0
-0.33
Return on equity %
1.37
-0.01
-0.3
-0.8
0
-0.37
Return on invested capital %
1 968.06
197.11
-756.24
-4 024.13
-1 283.14
-4 761.62
Gross margin %
—
100
100
100
100
400
Operating margin %
—
19.49
-2 423.88
628.98
-10.31
-5 502.09
EBITDA margin %
—
—
—
—
—
—
Net margin %
—
-3.93
-2 151.73
573.59
0.07
-5 071.33
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
3.85
8.26
20.34
8.69
14.75
51.36
Inventory turnover
—
—
—
—
—
—
Asset turnover
0
0.41
0.01
-0.09
0.49
0.2
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
0.09
0
—
—
—
—
Long term debt to total equity ratio
0.15
0
—
—
—
—
Per share metrics
Operating cash flow per share
4.67
-0.86
-2.29
-2.25
-0.23
-0.96
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
6
8.73
6.22
4.18
3.99
13.82
Net current asset value per share
7.73
9.07
6.53
4.34
4.12
14.3
Tangible book value per share
4.68
8.91
6.82
3.87
3.87
13.27
Working capital per share
5.72
7.97
6.21
3.84
3.84
13.15
Book value per share
4.68
8.91
6.82
3.87
3.87
13.27
新闻
Relay Therapeutics, Inc. (RLAY) Reports Q4 Loss, Lags Revenue Estimates
Lipocine completes patient visits in phase 3 trial for PPD treatment
H.C. Wainwright上调Lipocine目标股价至15美元,因PPD试验进展
H.C. Wainwright raises Lipocine stock price target to $15 on PPD trial progress
Lipocine completes enrollment in phase 3 trial for PPD treatment
利波辛公司产后抑郁症药物试验在安全性评估后继续进行
Lipocine’s PPD drug trial continues after positive safety review
Lipocine公司在产后抑郁症药物试验中完成80%的入组
Lipocine reaches 80% enrollment in postpartum depression drug trial
Lipocine在美国癫痫学会年会上展示LPCN 2101癫痫候选药物数据
Lipocine presents LPCN 2101 epilepsy candidate data at annual AES meeting
Lipocine公司III期临床试验安全性评估显示PPD治疗结果积极